A new magnetic nanocapsule containing 5-fluorouracil: In vivo drug release,anti-tumor,and pro-apoptotic effects on CT26 cells allograft model

Abstract

The purpose of this study was to create an optimized method for preparation of 5-fluorouracil-loaded magnetic poly lactic-co-glycolic acid nanocapsules and to investigate its potential as multifunctional carriers to deliver therapeutic agents for tumor-targeted therapies. The in vitro release of the newly synthesized 5-fluorouracil-loaded poly lactic-co-glycolic acid magnetic nanocapsules was investigated in phosphate-buffered saline medium using the dialysis method. In vivo release studies of the magnetic nanocapsules were performed in rabbits. Finally, the targeting properties, anti-tumor, and pro-apoptotic effects of this new magnetic nanocapsule on CT26 cells allograft model were studied. The effective diameter of nanocapsules was 67.2 nm. In vivo release investigations showed that 5-fluorouracil has a sustained release profile, prolonged lifetime in the rabbit plasma, and increased tissue appetency when loaded into the magnetic nanocapsule. Magnetic resonance imaging confirmed that the magnetic nanocapsules were successfully targeted to the tumor. Additionally, the anti-tumor studies revealed that the targeted therapy with magnetic nanocapsules containing 5-fluorouracil effectively inhibits the growth of tumors compared with 5-fluorouracil alone (P < 0.01). The present study demonstrates that this new magnetic nanocapsule can be considered a new nanotechnology-based cancer chemotherapy agent in vivo.

Keywords

Colon cancer nanotechnology PLGA 5-fluorouracil magnetic nanocapsule

Get full access to this article

View all access options for this article.

References

Haggar

Boushey

. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22: 191–197.

Alexiou

Tietze

Schreiber

. Cancer therapy with drug loaded magnetic nanoparticles-magnetric drug targeting. J Magn Magn Mater 2011; 323: 1404–1407.

Nair

Jagadeeshan

Nair

. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomed 2011; 6: 1685–1697.

Thomas

Kapanen

Hare

. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J Control Release 2011; 150: 212–219.

Kaiser

Kimpfler

Massing

. 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. Int J Pharm 2003; 256: 123–131.

Choi

Choy

. Biocompatible nanoparticles intercalated with anticancer drug for target delivery: pharmacokinetic and biodistribution study. J Nanosci Nanotechnol 2010; 10: 2913–2916.

Acharya

Sahoo

. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011; 63: 170–183.

Wang

Jiang

. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer 2008; 8: 103–103.

Nagarwal

Kumar

Pandit

. Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci 2012; 47: 678–685.

10.

Ashjari

Khoee

Mahdavian

. A multiple emulsion method for loading 5-fluorouracil into a magnetite-loaded nanocapsule: a physicochemical investigation. Polym Int 2012; 61: 850–859.

11.

Gong

Zhang

Liu

. Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model. Hepatobiliary Pancreat Dis Int 2004; 3: 365–368.

12.

Hajikarimi Z, Khoei S, Khoee S, et al. Evaluation of the cytotoxic effects of PLGA coated iron oxide nanoparticles as a carrier of 5-fluorouracil and the mega voltage X-ray radiation in DU145 prostate cancer cell line. IEEE Transaction on Nanobioscience. Submited.

13.

Mohammadi

Khoei

Mahdavi

. The combination effect of poly(lactic-co-glycolic acid) coated iron oxide nanoparticles as 5-fluorouracil carrier and X-ray on the level of DNA damages in the DU 145 human prostate carcinoma cell line. J Bionanosci 2012; 6: 23–27.

14.

Lin

Hsiue

. Preparation and characterization of intelligent core-shell nanoparticles based on poly(D,L-lactide)-g-poly(N-isopropyl acrylamide-co-methacrylic acid). J Control Release 2005; 104: 477–488.

15.

Simeonova

Velichkova

Ivanova

. Poly(butylcyanoacrylate) nanoparticles for topical delivery of 5-fluorouracil. Int J Pharm 2003; 263: 133–140.

16.

Zhang

Diasio

. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433–5438.

17.

Nagaich

Khopade

Jain

. Lipid grafts of egg-box complex: a new supramolecular biovector for 5-fluorouracil delivery. Pharm Acta Helv 1999; 73: 227–236.

18.

Yan

Chen

. Nanoparticles of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) for cancer chemotherapy: preparation, characterization–in-vitro drug release and anti-tumour activity. J Pharm Pharmacol 2006; 58: 1177–1181.

19.

Wang

Xiao

Zheng

. Effect of targeted magnetic nanoparticles containing 5-FU on expression of bcl-2, bax and caspase 3 in nude mice with transplanted human liver cancer. World J Gastroenterol 2007; 13: 3171–3175.